OPN305-102: A three-part, multi-center, randomized, double-blind, placebo-controlled, parallel-group, sequential adaptive, phase II study to evaluate the safety, tolerability and efficacy of OPN-305, a humanized, monoclonal antibody that blocks toll-like receptor 2, in renal transplant patients at high risk of delayed graft function.
0113-CL-2001: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV) – Seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-seropositive Donor.
Principal Investigator: Fredric Regenstein, MD
OCR002-HE209: Multicenter, Randomized, Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (ornithine phenylacetate) in Hospitalized Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated Patients with Cirrhosis and Associated Hyperammonia with an Episode of Hepatic Encephalopathy. STOP-HE Study